Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Recombinant Der f 4 is a recombinant version of the group 4 allergen derived from the house dust mite species *Dermatophagoides farinae*. It is a 57.9-kDa hydrophilic protein with a secondary structure characterized by alpha helices, extended strands, and random coils, consistent with the structure of alpha-amylase. In clinical research, rDer f 4 has demonstrated significant IgE reactivity, with approximately 40.7% of pediatric asthma patients sensitized to house dust mites showing positive results in ELISA testing. The protein is typically produced using an *E. coli* expression system and purified via nickel affinity chromatography. It is being investigated for its potential clinical utility as a diagnostic tool and as a component in allergen-specific immunotherapy (ASIT) for the treatment of house dust mite-induced allergic conditions such as asthma and rhinitis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on recombinant Der f 4.